The new EUR 1 billion buyback signals confidence in cash flow and supports EPS accretion. Monitor execution pace and any updates on 5008X launch adoption for further upside.
Price Chart
Executive Summary
Fresenius Medical Care held its 2026 AGM, approving a EUR 1.49 dividend (up from EUR 1.44), completing a EUR 1 billion buyback (8.5% of shares cancelled), and authorizing a new EUR 1 billion buyback over 12 months. Management highlighted improved operating margins (11.3%) and reduced leverage (2.5x), along with the U.S. commercial launch of the 5008X CAREsystem.
Key Facts
- Dividend of EUR 1.49 per share approved for FY2025, up from EUR 1.44.
- Completed EUR 1 billion share buyback, repurchasing 24.8 million shares (8.5% of capital).
- New EUR 1 billion buyback program announced with phased execution over 12 months.
- Group operating margin (adjusted) improved to 11.3% from 7.9% three years ago.
- Net leverage reduced to 2.5x from 3.4x in 2022.
- FDA approval of hemodiafiltration-capable 5008X CAREsystem; U.S. commercial launch underway in 2026.
Financial Impact
EUR 1 billion new buyback program; dividend increase of EUR 0.05 per share (approx. 3.5% increase).
Risk Factors
- Geopolitical uncertainty and healthcare regulatory changes could impact margins.
- Execution risk on 5008X commercial rollout and adoption in U.S. clinics.
- Potential adverse currency effects given global operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-066087 |
| Document: tm2615614d1_6k.htm | 0001104659-26-066087 |
| Document: tm2615614d1_ex99-4.htm | 0001104659-26-066087 |
| Document: tm2615614d1_ex99-2.htm | 0001104659-26-066087 |
| Document: tm2615614d1_ex99-3.htm | 0001104659-26-066087 |
| Document: 0001104659-26-066087-index-headers.html | 0001104659-26-066087 |
| Document: 0001104659-26-066087-index.html | 0001104659-26-066087 |
| Document: 0001104659-26-066087.txt | 0001104659-26-066087 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 28, 2026 21w ago | 6-K | $42.00 $51.44 | ▲ +22.48% | ▲ +20.74% | $43.82 (+4.33%) |
May 26, 2026 22w ago | 6-K | $42.00 $51.44 | ▲ +22.48% | ▲ +19.75% | $43.82 (+4.33%) |
May 5, 2026 25w ago | 6-K | $43.08 $49.82 | ▼ −15.65% | ▼ −12.91% | $43.82 (−1.72%) |
Apr 14, 2026 28w ago | 6-K | $44.25 $44.59 | ▲ +0.77% | ▼ −7.75% | $43.82 (−0.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers